An Open-Label, Single-Arm, Dose-Escalation Phase I Clinical Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection
Latest Information Update: 18 Aug 2025
At a glance
- Drugs WGc 0201 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Acronyms WGc0201-HBV
Most Recent Events
- 14 Jul 2025 New trial record